Trial Profile

The fourth Phase II "Lithium in Brain" clinical trial at Massachusetts General Hospital (MGH) - Phase IIA clinical trial assessing AL001 for treatment of Post-Traumatic Stress Disorder.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2026 According to the Alzamend Neuro media release, the 3rd, 4th, and 5th studies in the "Lithium in Brain" program enrolling patients with MDD, PTSD and Alzheimer's, respectively,are expected to begin in the latter half of 2026.
23 Jul 2025 According to the Alzamend Neuro media release, the topline results are expected by year-end 2025.
16 Jun 2025 According to the Alzamend Neuro media release, the company announced $5 million in gross proceeds from this Financing received, The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies at Massachusetts General Hospital.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com